Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04507997 · ClinicalTrials.gov registry record
Angelman Syndrome Natural History Study
A clinical trial of Angelman Syndrome, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 300
- Enrollment target
- 11
- Study locations
NCT04507997: Recruiting study of Angelman Syndrome, sponsored by Boston Children's Hospital.
NCT04507997 is a study of Angelman Syndrome that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 300 participants, above the 99-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (203% higher). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04507997, a study of Angelman Syndrome, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 11
- Study locations
Study Summary
The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future clinical trials.
Primary Outcome
Includes various medical complications, including seizure history
Conditions Studied
Study Locations (11)
California
- Cedars-Sinai Guerin Children's - Los Angeles
- Rady Children's Hospital, San Diego - San Diego
Colorado
- Children's Hospital Colorado, Anschutz Medical Campus - Aurora
Georgia
- Emory University School of Medicine - Atlanta
Illinois
- Rush University Children's Hospital - Chicago
Massachusetts
- Boston Children's Hospital - Boston
North Carolina
- The Carolina Institute for Developmental Disabilities - Carrboro
Tennessee
- Monroe Carell Jr. Children's Hospital at Vanderbilt - Nashville
Alberta
- Alberta Children's Hospital - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2031-04 |
What NCT04507997 shows while recruiting
NCT04507997 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 99-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (203% higher).
The record links to 1 condition, with Angelman Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT04507997 lists 11 locations in 10 states (California, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT04507997 about?
NCT04507997 is a clinical study titled "Angelman Syndrome Natural History Study". The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future clinical trials.
What is the current status of trial NCT04507997?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2018-08-01. Estimated completion is 2031-04.
What conditions does trial NCT04507997 study?
This clinical trial studies the following conditions: Angelman Syndrome.
Who is sponsoring clinical trial NCT04507997?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04507997 being conducted?
This trial has 11 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angelman Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04507997's enrollment target sits among peer trials
300 2nd of 11 the highest of 11 other Angelman Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Angelman Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
RECRUITING · Phase 3
-
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
RECRUITING · Phase 1
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
RECRUITING · Phase 2
-
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
RECRUITING · Phase 1
-
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI